

***Salmonella*-induced thrombi in mice develop asynchronously in the spleen and liver and are not effective bacterial traps**

**Short title:**

***Salmonella*-induced thrombi do not trap bacteria**

Nonantzin Beristain-Covarrubias<sup>1\*</sup>, Marisol Perez-Toledo<sup>1\*</sup>, Adriana Flores-Langarica<sup>1</sup>, Malou Zuidscherwoude<sup>2,4</sup>, Jessica R Hitchcock<sup>1</sup>, Will M. Channell<sup>1</sup>, Lloyd D.W. King<sup>1</sup>, Mark R. Thomas<sup>2</sup>, Ian R. Henderson<sup>3</sup>, Julie Rayes<sup>2</sup>, Steve P. Watson<sup>2,4</sup>, and Adam F. Cunningham<sup>1</sup>

<sup>1</sup>Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, UK; <sup>2</sup>Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, UK; <sup>3</sup>Institute for Microbiology and Infection, College of Medical and Dental Sciences, University of Birmingham, UK; and <sup>4</sup>Centre of Membrane Proteins and Receptors, Universities of Birmingham and Nottingham, The Midlands, UK

\* N.B.C. and M.P.T. contributed equally to this work.

**Corresponding authors:**

Adam F. Cunningham, <sup>1</sup>Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, B15 2TT, UK. [A.f.cunningham@bham.ac.uk](mailto:A.f.cunningham@bham.ac.uk). Phone: +441214144068, Fax: +441214143599

Steve P. Watson, <sup>2</sup>Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, B15 2TT, UK. [S.p.watson@bham.ac.uk](mailto:S.p.watson@bham.ac.uk). Tel: +441214146514

Text word count: 1192

Abstract word count: 195

Figures: 2

Tables: 0

References: 19

Key words: Immunothrombosis, platelets, monocytes, inflammation, podoplanin, *Salmonella*

35 **Key points:**

- 36 • Thrombosis develops in the spleen and liver with distinct kinetics following *Salmonella*
- 37 infection
- 38 • Thrombi in the spleen and liver are not major sites of bacterial localisation

39 **Abstract**

40 Thrombosis is a frequent, life-threatening complication of systemic infection, associated with multiple  
41 organ damage. We have previously described a novel mechanism of inflammation-driven thrombosis  
42 induced by *Salmonella* Typhimurium infection of mice. Thrombosis in the liver develops 7 days post-  
43 infection persisting after the infection resolves, and is monocytic cell-dependent. Unexpectedly,  
44 thrombosis was not prominent in the spleen at this time, despite carrying a similar bacterial burden as  
45 the liver. In this study, we show that thrombosis does occur in the spleen but with strikingly  
46 accelerated kinetics compared to the liver, being evident by 24 h and resolving rapidly thereafter. The  
47 distinct kinetics of thrombosis and bacterial burden provide a test of the hypothesis that thrombi form  
48 in healthy vessels to trap or remove bacteria from the circulation, often termed immunothrombosis.  
49 Remarkably, despite bacteria being detected throughout infected spleens and livers in the early days  
50 of infection, immunohistological analysis of tissue sections show that thrombi contain very low  
51 numbers of bacteria. In contrast, bacteria are present throughout platelet aggregates induced by  
52 *Salmonella in vitro*. Therefore, we show that thrombosis develops with organ-specific kinetics and  
53 challenge the universality of immunothrombosis as a mechanism to capture bacteria *in vivo*.

54 **Introduction**

55 The consequences of thrombosis are the leading cause of death worldwide<sup>1</sup>. Thrombosis is common  
56 after infection and can lead to organ failure and poor outcome<sup>2-5</sup>. There are however significant gaps  
57 in our understanding of blood-borne infection-associated thrombosis, including whether it occurs at  
58 multiple sites through distinct mechanisms and/or kinetics<sup>2</sup>. Immune-driven thrombosis, broadly-  
59 termed “immunothrombosis”, can occur in the presence or absence of infection. Nevertheless, when

triggered by infection, it is still unclear whether the induced thrombi capture and contain blood-borne pathogens within the vasculature as proposed<sup>6-8</sup>.

We recently reported on a novel pathway of thrombosis in the liver after infection with *Salmonella* Typhimurium (STm), involving inflammation-driven upregulation of podoplanin on monocytic cells and activation of platelets<sup>9</sup>. A striking feature of this thrombosis is that it takes a week to develop and then persists as the bacterial burden declines. Furthermore, thrombi are largely undetectable in the spleen at this time, despite this organ being a major site of bacterial colonisation<sup>10,11</sup>. In this paper, we show that extensive thrombosis does occur in the spleen but is rapid in onset and transient, with distinct kinetics to liver. Furthermore, we show that thrombi present in either organ contain surprisingly few bacteria, despite the high bacterial burdens in the organs themselves, indicating that bacterial entrapment is not a major consequence of thrombosis after infection with STm.

## **Study design**

### **Full details are provided in the Supplemental Material**

#### **Mice and infection with STm**

Wild-type (WT), C57BL/6 mice (Home Office Licenses 3028/50 and P2E63AE7B) were infected intraperitoneally (i.p.) or intravenously (i.v.) with  $1-5 \times 10^5$  attenuated SL3261 or virulent SL1344 STm<sup>12,13</sup>.

#### **Immunohistology and fluorescent microscopy**

Cryosections were stained for immunohistochemistry (IHC) or immunofluorescence (IF)<sup>13,14</sup> to detect CD41, CD31, fibrin/fibrinogen, Ly6G, Ly6C, F4/80, *Salmonella* and nuclei (DAPI; Supplemental Table 1)<sup>9</sup>.

#### **Clodronate treatment**

Mice were treated i.p. with either 200  $\mu$ l (5 mg/ml) of clodronate or PBS liposomes 24 h before STm infection<sup>15,16</sup>.

## 84 Results and Discussion

### 85 Thrombosis develops with distinct kinetics in the spleen and liver

86 Thrombosis in the liver becomes established 7 days after infection, whereas few thrombi are  
 87 detectable in the spleen at this time<sup>9</sup>. In the liver, thrombosis is driven by the up-regulation of  
 88 podoplanin on monocytes/macrophages, triggering activation of CLEC-2 on platelets<sup>9</sup>. The spleen is  
 89 a reservoir of monocytic cells, with high numbers of these cells present pre-infection compared to the  
 90 liver, and 24 hours post-infection there were increased numbers of inflammatory splenic monocytes  
 91 (Supplemental Figure S1), suggesting that thrombosis may occur at a much earlier stage in the  
 92 infection. Consistent with this, we found numerous, large platelet-rich thrombi within the spleen at 24  
 93 h post-infection (Figure 1A), independent of whether mice were infected i.v. or i.p. or of the virulence  
 94 of the infecting strain (Figure 1B-C). Thrombi typically stained positive for citrullinated-histone H3,  
 95 Ly6G<sup>+</sup> cells and myeloperoxidase (Supplemental Figure S2). Ly6C<sup>+</sup> and F4/80<sup>+</sup> cells were located at  
 96 the periphery of thrombi (Supplemental Figure S3). Splenic thrombosis resolved rapidly after day 1,  
 97 with few thrombi detected thereafter (Figure 1D,E), often leaving the remnants of a fibrin core (Figure  
 98 1 and 2A). In contrast, at these early times, thrombosis was undetectable in the liver (Figure  
 99 1B,C,D,F). Moreover, thrombosis was absent in the spleens of clodronate-liposome treated mice  
 100 (Figure 1G) suggesting that, like in the liver, monocytic cells are important in this process<sup>9</sup>. Therefore,  
 101 systemic infection with STm can induce thrombosis in distinct sites and with distinct kinetics, likely  
 102 due to the levels of tissue-resident macrophages present at the time of infection.

### 103 Most thrombi induced in the spleen and liver contain limited numbers of bacteria

104 It has been proposed that thrombus formation can trap and remove bacteria, a process sometimes  
 105 known as immunothrombosis<sup>6</sup>. After platelet activation induced by STm *in vitro*, bacteria are present  
 106 throughout the aggregate as shown in Supplemental Figure S4 and video 1. This demonstrates that  
 107 bacteria can closely associate with platelets in aggregates formed *in vitro*. We used IHC and IF  
 108 microscopy to identify the relationship between bacterial localisation and thrombi *in vivo* at the peak  
 109 times of thrombosis in the spleen (day 1) and liver (day 7) (Figure 2A-B and Supplemental Figure

S5). A 3-dimensional reconstruction of a thrombus and proximal bacteria is shown in Supplemental Figure S6 and Supplemental Video 2. Collectively, these approaches all showed that thrombi contained a surprisingly low number of bacteria, despite their relative abundance in the surrounding tissues. Quantification of the bacteria within sections of splenic thrombi (>200 thrombi from 37 mice, 3 time points evaluated) showed that no bacteria were detected in 38% of thrombus sections at day 1, and that 33% of sectioned thrombi contained 1-2 bacteria (Figure 2C). At later times, bacteria were detected at an even lower frequency within sections of splenic thrombi, with >90% of thrombi containing 0-2 bacteria at day 7 and day 21 (Figure 2C). In the liver, only ~20% of thrombi sections (>400 thrombi counted from 23 mice) contained bacteria at day 7 and this proportion was even lower (<5%) at day 21 (Figure 2D). Analysis of serial sections from the same thrombi confirmed a paucity of bacteria within individual thrombi (Supplemental Figure S7). When the bacterial burdens per organ were compared with the levels of thrombosis at days 1 to 21 post-infection, no direct relationship was found between the two, other than the necessity for infection to induce thrombosis. In the spleen, thrombosis peaks before bacterial numbers peak (Figure 2E) and falls whilst bacterial numbers are still rising, whereas in the liver thrombosis develops later and peaks when the bacterial levels are beginning to decline (Figure 2F)<sup>9,13,17</sup>. Therefore, thrombi induced during this infection do not trap significant numbers of bacteria, regardless of the bacterial loads in the organs. This contrasts with other models of infection<sup>18,19</sup>, which used 1000-fold higher numbers of bacteria compared to here<sup>9</sup>. Thus, although STm infection can drive thrombosis, thrombi do not necessarily contribute to bacterial containment and moreover they form in different organs with distinct kinetics. These findings are important for our understanding of the consequences of infection on the haematological system since they show that the presence of equivalent levels of bacteria is not enough to induce thrombosis in an organ.

Although these data show that during a single infection thrombosis can occur sequentially in multiple tissues, further work is needed to evaluate whether other systemic bacterial infections induce thrombosis with similar kinetics. Thrombi are induced by many different pathogens and although the role of thrombosis after infection remains unclear, the presumption must be that they are pathological

in some circumstances, particularly if they are large and/or embolise. Since we have shown that thrombi develop in the venous system, they may form due to differences in local infection-associated changes in blood flow and as part of altered vessel homeostasis. Perhaps the bigger clinical question is about what controls their ultimate size and what triggers thrombus resolution as this may influence whether thrombosis becomes clinically problematic. Therefore, for a known infection it may be possible to target therapeutically those organs at greatest risk of developing thrombosis at particular stages of infection. These findings deepen our understanding of the concept of immunothrombosis and shows thrombi can form as a non-canonical haemostatic response to infection-driven inflammation but not to capture bacteria.

## **Acknowledgements**

The authors wish to thank the staff of the BMSU for their assistance. The authors would like to acknowledge the Imaging Suite at the University of Birmingham for support. This work was supported by grants from the Medical Research Council (MR/N023706/1) and the British Heart Foundation (BHF) (RG/13/18/30563). N.B.C. was supported by National Council of Science and Technology (CONACYT)-Mexico overseas postdoctoral fellowship (CVU 332390). S.P.W. is a BHF Chair (CH/03/003).

## **Authorship**

Contribution: N.B.C. and M.P.T. designed and performed the experiments, analysed the data and wrote the manuscript; A.F.L., M.Z., J.R.H., L.D.W.K., W.M.C. performed the experiments and analysed the data; M.R.T., J.R. contributed vital reagents, experimental design and proofread the manuscript; I.R.H. experimental design, novel reagents and proofread the manuscript; A.F.C. and S.P.W. supervised the research, analysed the data, and wrote the manuscript.

## **Conflict-of-interest disclosure:**

The authors declare no competing financial interests.

## **References**

1. World Health Organization. Fact Sheet The Top Ten Causes of Death. Vol. 2015; 2015.
2. Furie B, Furie BC. Mechanisms of thrombus formation. *N Engl J Med*. 2008;359(9):938-949.
3. Pawlinski R, Pedersen B, Schabbauer G, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. *Blood*. 2004;103(4):1342-1347.
4. Pawlinski R, Wang JG, Owens AP, 3rd, et al. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. *Blood*. 2010;116(5):806-814.
5. Angus DC, van der Poll T. Severe sepsis and septic shock. *N Engl J Med*. 2013;369(9):840-851.
6. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. *Nature Reviews Immunology*. 2013;13(1):34-45.
7. van der Poll T, Herwald H. The coagulation system and its function in early immune defense. *Thromb Haemost*. 2014;112(4):640-648.
8. Davis RP, Miller-Dorey S, Jenne CN. Platelets and coagulation in infection. *Clin Transl Immunology*. 2016;5(7):e89.
9. Hitchcock JR, Cook CN, Bobat S, et al. Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets. *Journal of Clinical Investigation*. 2015;125(12):4429-4446.
10. Monack DM, Mueller A, Falkow S. Persistent bacterial infections: The interface of the pathogen and the host immune system. *Nature Reviews Microbiology*. 2004;2(9):747-765.
11. Mastroeni P, Grant A, Restif O, Maskell D. A dynamic view of the spread and intracellular distribution of Salmonella enterica. *Nat Rev Microbiol*. 2009;7(1):73-80.
12. Cunningham AF, Khan M, Ball J, et al. Responses to the soluble flagellar protein FlhC are Th2, while those to FlhC on Salmonella are Th1. *Eur J Immunol*. 2004;34(11):2986-2995.
13. Cunningham AF, Gaspal F, Serre K, et al. Salmonella induces a switched antibody response without germinal centers that impedes the extracellular spread of infection. *Journal of Immunology*. 2007;178(10):6200-6207.
14. Flores-Langarica A, Marshall JL, Bobat S, et al. T-zone localized monocyte-derived dendritic cells promote Th1 priming to Salmonella. *European Journal of Immunology*. 2011;41(9):2654-2665.
15. Buiting AM, Van Rooijen N. Liposome mediated depletion of macrophages: an approach for fundamental studies. *J Drug Target*. 1994;2(5):357-362.
16. Van Rooijen N. The liposome-mediated macrophage 'suicide' technique. *J Immunol Methods*. 1989;124(1):1-6.
17. Gil-Cruz C, Bobat S, Marshall JL, et al. The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response. *Proc Natl Acad Sci U S A*. 2009;106(24):9803-9808.
18. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nature Medicine*. 2010;16(8):887-U887.
19. Gaertner F, Ahmad Z, Rosenberger G, et al. Migrating Platelets Are Mechano-scavengers that Collect and Bundle Bacteria. *Cell*. 2017;171(6):1368-1382 e1323.

## Figure legends

### Figure 1. Thrombosis in the spleen and liver follows different kinetics after STm infection. (A)


Frozen spleens from WT mice infected with  $5 \times 10^5$  STm i.p were sectioned longitudinally to the hilum ( $\geq 1200 \mu\text{m}$  deep) and  $5\text{-}\mu\text{m}$  sections were stained by IHC. Scans of stained spleen sections from day 0, 1, 7 and 21-infected mice show blood vessels identified with anti-CD31 in blue and thrombi with anti-fibrin/fibrinogen in brown. Arrows identify individual thrombi. (B) Representative low power

images of spleen and liver sections stained for CD41 (platelets; blue) and fibrin/fibrinogen (brown) from mice infected for 24 hours via the i.v. route with  $5 \times 10^5$  STm SL3261. The left hand graph shows the number of thrombi per spleen section for mice infected i.p. or i.v. The right hand graph shows the number of thrombi per section in the spleen and liver from these i.v. infected mice. (C) Representative low power images of spleen and liver sections stained for CD41 (platelets; blue) and fibrin/fibrinogen (brown) from mice infected for 24 hours with the virulent  $10^5$  STm SL1344 strain. The left hand graph shows the number of thrombi per spleen section for mice infected with SL3261 (attenuated) or SL1344 (virulent). The right hand graph shows the number of thrombi per section in the spleen and liver from mice infected with SL1344. (D) Representative scans at higher magnification of spleen sections (upper panels) and liver sections (lower panels) from WT mice at day 0, 1, 7 and 21 post-infection with  $5 \times 10^5$  STm SL3261. Sections are stained for fibrin/fibrinogen (brown) and CD41 (blue). V=Vein, RP=Red Pulp, WP=White Pulp, T=Thrombus. (E) Quantification of numbers of thrombi per spleen section (left graph) and the proportion of section area covered by thrombi (right graph) at days 0, 1, 2, 7 and 21 after infection with  $5 \times 10^5$  STm SL3261. Each point represents a single mouse (Data are combined from 3 independent experiments);  $*p < 0.05$ , 1 way ANOVA. (F) Line graph showing the level of thrombosis in the spleen (black line) and the liver (grey line) over the first 3 weeks of infection with  $5 \times 10^5$  STm SL3261. The data are expressed as mean  $\pm$  S.E.M. from at least 4 mice per group combined from 3 independent experiments. (G) Quantification of thrombi in spleen sections from PBS liposomes or clodronate liposome pre-treated mice, infected for 24 hours with  $5 \times 10^5$  STm SL3261. Combined data from 2 experiments with a total of 8 mice in each group.  $*p < 0.05$ . 2-tailed non-parametric t test. N.D.=Not detected.




**Figure 2. Detection of bacteria within thrombi.** Representative immunofluorescence photomicrographs of (A) spleens and (B) livers from WT mice infected with  $5 \times 10^5$  STm SL3261 for 0, 1, 7 and 21 days. (V=Vein, RP=Red Pulp, WP=White Pulp, T=Thrombus, MK=Megakaryocyte). Fibrin, blue; CD31, white; CD41, red and STm, green indicated with white arrows. For both (A) and (B) the second row shows a higher magnification image of the area identified by the white box. (C) and (D) Frequency of detecting 0, 1, 2 or  $\geq 3$  bacteria in thrombi in sections from spleens and livers



233 respectively, infected with  $5 \times 10^5$  STm SL3261 for 0, 1, 7 or 21 days. (E) and (F) Line graphs showing  
234 the kinetics of thrombosis (black) and bacterial colonisation (gray) in spleens and livers respectively,  
235 from mice infected with  $5 \times 10^5$  STm SL3261 for 0, 1, 2, 7 or 21 days. Data are expressed as mean  $\pm$   
236 S.E.M. from 152 thrombi counted in spleens from day 1; 40 from day 7; and 18 from day 21-infected  
237 mice. In liver, 411 thrombi were counted for day 7 and 23 for day 21 after infection. In each case  
238 thrombi were counted from at least 4 mice per group and are combined from 3 independent  
239 experiments. CFU= Colony-forming unit.









Prepublished online November 6, 2018;  
doi:10.1182/blood-2018-08-867267

## **Salmonella-induced thrombi in mice develop asynchronously in the spleen and liver and are not effective bacterial traps**

Nonantzin Beristain-Covarrubias, Marisol Perez-Toledo, Adriana Flores-Langarica, Malou Zuidscherwoude, Jessica R. Hitchcock, Will M. Channell, Lloyd D.W. King, Mark R. Thomas, Ian R. Henderson, Julie Rayes, Steve P. Watson and Adam F. Cunningham

---

Information about reproducing this article in parts or in its entirety may be found online at:  
[http://www.bloodjournal.org/site/misc/rights.xhtml#repub\\_requests](http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:  
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:  
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>

---

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.